TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02414191

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Benchmarked Feedback
Description: Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of benchmarked feedback, which is the measure of their performance in comparison the standard set by the hospital.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ranked Feedback
Description: Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of ranked feedback, which is the measure of their performance in comparison to their peers.
Study: NCT03694639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ganglion impar block
Description: CT sections were done in the axial plane 4 mm slice thickness to detect the site of sacrococcygeal disk. After a suitable section was confirmed, two distances were measured, one from patient's spine to the proper site of entry and the other from the site of entry to the target point.22 gauge spinal needle 12 cm was introduced until reach anterior to sacrococcygeal disk. When the needle tip location was ideal, 2 ml lidocaine mixed with1ml of radiopaque dye was injected. CT sagittal section was done to verify the retroperitoneal distribution of the dye. After good contrast spread confirmation, 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone was injected
Study: NCT00680511

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adolescent Methamphetamine Treament (AMT)
Description: AMT Group Therapy plus Functional Family Therapy (FFT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Family Therapy (FFT)
Description: FFT
Study: NCT03332368

Intervention type: OTHER
Intervention: Traditional Chinese medicine
Description: Chinese medicine has a long history of prevention and treatment of breast cancer, the effect is obvious. Chinese medicine its mechanism of action is from the whole, adjust the body yin and yang, blood, viscera function balance, emphasizing the combination of governance and external treatment of the combination of thinking, according to different clinical syndromes, using syndrome differentiation.
Study: NCT04866212

Intervention type: BEHAVIORAL
Intervention: Beery- Buktenica Developmental Test of Visual Motor Integration
Description: Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.

Intervention type: BEHAVIORAL
Intervention: Beery- Buktenica Developmental Test of Visual Motor Integration
Description: Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.

Intervention type: BEHAVIORAL
Intervention: Jebsen Taylor Hand Function Test
Description: Investigation of hand skills by Jebsen Taylor Hand Function Test

Intervention type: BEHAVIORAL
Intervention: Jebsen Taylor Hand Function Test
Description: Investigation of hand skills by Jebsen Taylor Hand Function Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Participation and Environment Measure - Children and Youth
Description: Investigation of participation by Participation and Environment Measure - Children and Youth

Intervention type: DIAGNOSTIC_TEST
Intervention: Participation and Environment Measure - Children and Youth
Description: Investigation of participation by Participation and Environment Measure - Children and Youth
Study: NCT03278418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricuspid Valve Repair
Description: It will be performed according to the surgeon preference

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left-sided valve surgery
Description: It will be performed according to the surgeon preference

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left-sided valve surgery
Description: It will be performed according to the surgeon preference
Study: NCT03538015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 3.125 mg
Description: Participants will receive a 3.125 mg oral dose of carvedilol twice daily during the 4-week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 2.5 mg
Description: Participants will receive a 2.5 mg oral dose of carvedilol twice daily during the 4-week treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Participants will receive a matching oral dose of placebo capsule twice daily during the 4-week treatment period
Study: NCT00387855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOS program
Description: screening and didactic programming to raise awareness of depression suicidality
Study: NCT00912548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: 1. Zoladex™ administration:~   Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.~2. Sequence of administration Zoladex depot:~   The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).~3. Dosage:~   Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .~4. Storage instructions for Zoladex™ Zoladex™ is kept a room temperature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: 1. Zoladex™ administration:~   Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.~2. Sequence of administration Zoladex depot:~   The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).~3. Dosage:~   Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .~4. Storage instructions for Zoladex™ Zoladex™ is kept a room temperature.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: 1. Dose and period of Tamoxifen therapy:~   Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~2. Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: 1. Dose and period of Tamoxifen therapy:~   Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~2. Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: 1. Dose and period of Tamoxifen therapy:~   Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~2. Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: 1. Dose and period of Tamoxifen therapy:~   Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~2. Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light.
Study: NCT04406493

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung impedance technique
Description: COVID 19 patients are admitted to the Infectious Diseases Unit; they will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization, each patient will undergo this examination twice a day until discharge.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation.~The time between lung impedance started to decrease (expression of the lung fluids accumulation), and the need for mechanical ventilation will be measured.
Study: NCT03298646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: 10 ml of 2% lidocaine on hysteroscopic infusion media during office hysteroscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 100 mg Diclofenac oral tablet one hour before the procedure.
Study: NCT00698646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + HCTZ
Description: At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Description: At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
Study: NCT01400503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. Siltuximab given as a 1-hour infusion every 3 weeks.
Study: NCT02058615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Male Spouse Transition Toolkit
Study: NCT04674124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Online Mindfulness Intervention
Description: A nine-week mindfulness course compromising of 9x weekly 15 minute group sessions which will be on an online platform and daily micro meditations for participants to undertake.
Study: NCT00609427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEMO programme (Inst Universitaire de Geriatrie, Montreal)
Description: 8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External memory aids training
Description: 8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
Study: NCT03131557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Line extension of the Phonak Audéo B product family
Description: The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak Audéo B
Description: Phonak Audéo B will be fitted to the participants individual hearing loss.
Study: NCT02170740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS - low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS - high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS - high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS + Pantoprazole
Study: NCT03341793

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle biopsy and blood test
Description: Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
Study: NCT02721082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt Out Treatment Program
Description: Tobacco Treatment (UKanQuit) staff will complete a treatment plan for all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Unless they Opt Out all participants will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opt In Treatment Program
Description: Tobacco Treatment (UKanQuit) staff will complete a treatment plan for participant's who are ready to quit smoking. For patient's not ready to quit, motivational counseling will be provided to participants based on principles of Motivational Interviewing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Participants ready to quit will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
Study: NCT01001052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colcrys™ (colchicine)
Description: 0.6 mg taken by mouth on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colcrys™ (colchicine)
Description: 0.6 mg taken by mouth on day 1
Study: NCT00860379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium1
Description: 2 ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium2
Description: 4 ug/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV saline as placebo
Study: NCT01458197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarafenacin 0.2 mg
Description: Capsule, qd, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, qd, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarafenacin 0.4 mg
Description: Capsule, qd, 12 weeks
Study: NCT02415101

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resective surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resective surgery
Study: NCT02400138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory training
Description: Respiratory training will include training of the inspiratory and expiratory muscle seven times per week over eight weeks, during 40 minutes, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
Study: NCT03876405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartskin non-invasive sensory feedback
Description: The sensory feedback system used was a simple non-invasive, non-electronic system based on air-mediated pressure. A silicone glove with bulbs (35 mm in length) volar in every fingertip was made and applied on a VariPlus Speed hand (OttoBock), size 7¾.~The sensory feedback system was embedded in the prosthetic socket.
Study: NCT04944641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education on epilepsy
Description: education on epilepsy, including epilepsy diary, pamphlet，discussion between patients and phone visits and so on

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: routine and proper antiepileptic drugs
Description: routine and proper antiepileptic drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: routine and proper antiepileptic drugs
Description: routine and proper antiepileptic drugs
Study: NCT01474733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: series of lectures and workshops on health literacy
Study: NCT01015157

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y laparoscopic gastric bypass for morbid obesity
Description: Primary bariatric surgery. Standard laparoscopic procedure with linear stapling divising of the stomach (Echelon 60 stapler, GOLD cartridges) with or with Seamguard reinforcement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y laparoscopic gastric bypass for morbid obesity
Description: Primary bariatric surgery. Standard laparoscopic procedure with linear stapling divising of the stomach (Echelon 60 stapler, GOLD cartridges) with or with Seamguard reinforcement
Study: NCT01536132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: 0.2 micrograms/kg/min is administered intravenously without bolus for 6 hours every two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (same appearance than active drug) is administered with the same dosing regime
Study: NCT03532295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: -All BID doses will be taken in the morning and evening, approximately 12 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: -The first infusion will be over the course of 90 minutes; if tolerated, the second infusion will be over the course of 60 minutes; if tolerated, all subsequent infusions will be over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: -The first infusion will be over the course of 90 minutes; if tolerated, the second infusion will be over the course of 60 minutes; if tolerated, all subsequent infusions will be over 30 minutes

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -The gross tumor maximum diameter (to be irradiated) to be \</= 6 cm in the first 6 patients. If more than 1 target is irradiated, then the sum of all the target maximum diameters should be \</= 6 cm. No more than 3 separate targets for RT is allowed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -The gross tumor maximum diameter (to be irradiated) to be \</= 6 cm in the first 6 patients. If more than 1 target is irradiated, then the sum of all the target maximum diameters should be \</= 6 cm. No more than 3 separate targets for RT is allowed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: * Baseline (prior to administration of any study treatment)~* Before initiation of RT (up to 7 days prior to start of RT; may be on the same day as RT before RT treatment)~* At the end of RT and/or Cycle 2 Day 1 prior to administration of INCMGA00012 with our without epacadostat~* Cycle 3 Day 1 prior to administration of INCMGA00012 with or without epacadostat (+/- 7 days)~* Cycle 5 Day 1 prior to administration of INCMGA00012 with our without epacadostat (+/- 7 days)~* Time of disease progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: * Baseline (prior to administration of any study treatment)~* Before initiation of RT (up to 7 days prior to start of RT; may be on the same day as RT before RT treatment)~* At the end of RT and/or Cycle 2 Day 1 prior to administration of INCMGA00012 with our without epacadostat~* Cycle 3 Day 1 prior to administration of INCMGA00012 with or without epacadostat (+/- 7 days)~* Cycle 5 Day 1 prior to administration of INCMGA00012 with our without epacadostat (+/- 7 days)~* Time of disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: -Will be supplied by Incyte

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: -Will be supplied by Incyte
Study: NCT01298999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YF476
Description: 25 mg: one capsule to be taken by mouth once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
Study: NCT01543061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPTIVEtm Plus
Description: 1 drop in each eye four times a day for a period of 30 (± 3) days

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No treatment
Description: One month of contact lens wear with no eye drop use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blink Contacts® Eye Drops
Description: 1 drop in each eye four times a day for a period of 30 (± 3) days
Study: NCT04359472

Intervention type: DEVICE
Group type: OTHER
Intervention: Application of Autologous Amniotic Fluid
Description: Collection and reapplication of amniotic fluid at wound layers during a cesarean section.
Study: NCT00100685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volociximab (anti-α5β1 integrin monoclonal antibody)
Description: Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volociximab (anti-α5β1 integrin monoclonal antibody)
Description: Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first.
Study: NCT04560491

Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative examination of sentinel node
Description: Intraoperative examination of sentinel node by either frozen section or scrape cytology to detect metastasis and decide for further lymphadenectomy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative examination of sentinel node
Description: Intraoperative examination of sentinel node by either frozen section or scrape cytology to detect metastasis and decide for further lymphadenectomy.
Study: NCT03719755

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 50% dextrose
Description: maximum injection of 40 cc of 50% dextrose plus 300 cc of normal saline washout versus normal saline after hysterectomy for benign indications.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Cystoscopic distention media of normal saline
Study: NCT01190696

Intervention type: PROCEDURE
Group type: OTHER
Intervention: titanium elastic nailing
Description: we inserted titanium nail in femoral fractures retrogradely

Intervention type: DEVICE
Group type: OTHER
Intervention: Hip spica casting
Description: we applied cast for three weeks in patients with femoral shaft fracture